





VENABLE | Fitzpatrick


January 31, 2021











FWD = Final Written Decision



Spotlight On: Rituximab

January 31, 2021

Technology: Rituximab is a chimeric murine/human monoclonal antibody that is directed against the CD20 antigen. CD20 is a protein that is primarily found on the surface of immune system B cells. CD20 is involved in cell growth and differentiation.

| | Genentech v. Celltrion 1:18-cv- 11553 (D.N.J.) Settled Cont'd below | Genentech v. Celltrion 1:18-cv- 00574 (D.N.J.) Settled Cont'd below | Celltrion v. Genentech 4:18-cv-00276 (N.D. Cal.) Dismissed; Appeal No. 18- 2161 Dismissed | Genentech v. Sandoz 1:17-cv-13507 (D.N.J.) Dismissed Cont'd below | Celltrion v. Genentech IPR2017-01227 Institution denied | Celltrion v. Genentech IPR2017-01230 Institution denied | Pfizer v. Genentech IPR2017- 02126 Institution denied | Boehringer Ingelheim v. Genentech IPR2015-00415 Petitioner request for adverse judgment after institution | Celltrion v. Genentech IPR2015- 01744 Petitioner dismissed prior to institution decision | Celltrion v. Genentech IPR2016-01614 FWD (no instituted claim unpatentable); Appeal 18-1924 dismissed | Pfizer v. Genentech IPR2017-01115 (Joined with IPR2016-01614) FWD (no instituted claim unpatentable); Appeal 18-1885 dismissed (settled) |
|-----------|---|---|---|--|---|---|--|---|--|--|--|
| 6,121,428 | | X | | X | | | | | | | |
| 6,242,177 | | х | | | | | | | | | |
| 6,331,415 | x | х | x | x | | | | | | | |
| 6,417,335 | | х | Х | | | | | | | | |
| 6,455,043 | | х | X | | | | | | | | |
| 6,489,447 | х | х | Х | x | | | | | | | |
| 6,586,206 | | х | Х | | | | | | | | |
| 6,610,516 | х | х | Х | х | | | | | | | |
| 6,620,918 | х | х | Х | x | | | | | | | |
| 6,716,602 | | х | х | | | | | | | | |
| 6,870,034 | | | | x | | | | | | | |
| 7,381,560 | х | х | | x | | | | | | | |
| 7,390,660 | | х | X | | | | | | | | |
| 7,485,704 | х | х | Х | x | | | | | | | |
| 7,682,612 | | х | X | | X | х | х | | | | |
| 7,807,799 | х | х | Х | x | | | | | | | |
| 7,820,161 | х | х | х | x | | | | x | х | х | Х |
| 7,923,221 | x | x | x | x | Boehringer Ingelheim v. Genentech IPR2015-00417 Petitioner request for adverse judgment after institution | Celltrion v. Genentech IPR2015-01733 Petitioner dismissed prior to institution decision | Celltrion V. Genentech IPR2016- 01667 Institution denied | Pfizer v. Genentech IPR2017-01923 Settled after institution | Sandoz v. Genentech IPR2017- 02036 Institution denied | Sandoz v. Genentech IPR2017-02042 Institution denied | Celltrion v. Genentech IPR2018-01019 Joined with IPR2017-01923; Settled after institution |
| 7,976,838 | x | x | x | х | х | х | Х | х | х | х | Х |



Spotlight On: Rituximab

VENABLE | Fitzpatrick

January 31, 2021

| | Genentech v. Celltrion 1:18-cv-11553 (D.N.J.) Settled Cont'd from above | Genentech v. Celltrion 1:18-cv- 00574 (D.N.J.) Settled Cont'd from above | Celltrion v. Genentech 4:18-cv-00276 (N.D. Cal.) Dismissed; Appeal No. 18-2161 Dismissed Cont'd from above | Genentech v. Sandoz 2:17-cv-13507 (D.N.J.) Dismissed Cont'd from above | Celltrion v. Genentech IPR2017- 01229 Institution denied | Pfizer v. Biogen IPR2017- 02127 Institution denied | Boehringer Ingelheim v. Biogen IPR2015- 00418 Institution denied | Celltrion v. Biogen IPR2017-01093 Institution denied | Pfizer v. Biogen IPR2017-01166 Institution denied; Request for rehearing withdrawn | <i>Pfizer v. Biogen</i> IPR2018-00285 Settled after institution | |
|-----------|---|--|--|--|---|---|--|---|---|---|--|
| 8,044,017 | | x | х | | | | | | | | |
| 8,206,711 | x | х | Х | x | x | x | | | | | |
| 8,314,225 | | | | x | | | | | | | |
| 8,329,172 | х | х | X | x | | | Х | X | X | Х | |
| 8,357,301 | | x | X | | | | | Pfizer v. Biogen IPR2017-01168 FWD (All instituted claims unpatentable); Appeal 19-1364 affirmed with US, settled with Pfizer | Celltrion v. Biogen IPR2017-01095 FWD (All instituted claims unpatentable); Appeal 19-1253 dismissed as to US, settled with Celltrion | | |
| 8,460,895 | | x | X | | Pfizer v. | Celltrion v. | Pfizer v. Biogen IPR2017- 01167 Institution denied | | | Pfizer v. | Prizer V. Biogen PR2018- 00186 rminated after Prizer V. Biogen IPR2018-00231 Petitioner dismissed prior to institution |
| 8,512,983 | | x | x | × | IPR2018- IPR201 00086 0109- Institution Institut | Biogen IPR2017- 01094 Institution denied | | | | IPR2018- 00186 Terminated | |
| 8,545,843 | x | х | X | x | x | | | | | | |
| 8,557,244 | x | х | Х | x | | x | Х | | | | |
| 8,574,869 | х | x | X | x | | | | | | | |
| 8,633,302 | | х | Х | | | | | | | | |
| 8,710,196 | | х | Х | х | | | | | | | |
| 8,771,988 | | х | Х | | | | | | | | |
| 8,821,873 | x | х | х | х | | | | Х | | | |
| 8,822,655 | | х | х | | | | | | | | |
| 9,047,438 | | х | х | | | | | | | | |
| 9,080,183 | | х | Х | | | | | | | | |
| 9,296,821 | х | х | х | x | | | | | Х | х | |
| 9,428,548 | | х | х | | | | | | | | |
| 9,428,766 | | x | х | | | | | | | | |
| 9,487,809 | | х | Х | | | | | | | | |
| 9,504,744 | х | x | х | х | | | | | | | х |
| 9,714,293 | | х | Х | х | | | | | | | |